283 related articles for article (PubMed ID: 11752111)
1. Relationship between rate and extent of G protein activation: comparison between full and partial opioid agonists.
Traynor JR; Clark MJ; Remmers AE
J Pharmacol Exp Ther; 2002 Jan; 300(1):157-61. PubMed ID: 11752111
[TBL] [Abstract][Full Text] [Related]
2. G protein activation by endomorphins in the mouse periaqueductal gray matter.
Narita M; Mizoguchi H; Narita M; Dun NJ; Hwang BH; Endoh T; Suzuki T; Nagase H; Suzuki T; Tseng LF
J Biomed Sci; 2000; 7(3):221-5. PubMed ID: 10810240
[TBL] [Abstract][Full Text] [Related]
3. Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys.
Ko MC; Lee H; Harrison C; Clark MJ; Song HF; Naughton NN; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2003 Jul; 306(1):179-86. PubMed ID: 12676881
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
[TBL] [Abstract][Full Text] [Related]
5. Anatomical distribution of mu, delta, and kappa opioid- and nociceptin/orphanin FQ-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in guinea pig brain.
Sim LJ; Childers SR
J Comp Neurol; 1997 Oct; 386(4):562-72. PubMed ID: 9378852
[TBL] [Abstract][Full Text] [Related]
6. Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouse.
Mizoguchi H; Wu HE; Narita M; Hall FS; Sora I; Uhl GR; Nagase H; Tseng LF
Neuroscience; 2002; 115(3):715-21. PubMed ID: 12435410
[TBL] [Abstract][Full Text] [Related]
7. Acute and chronic effects of opioids on delta and mu receptor activation of G proteins in NG108-15 and SK-N-SH cell membranes.
Breivogel CS; Selley DE; Childers SR
J Neurochem; 1997 Apr; 68(4):1462-72. PubMed ID: 9084416
[TBL] [Abstract][Full Text] [Related]
8. Absence of G-protein activation by mu-opioid receptor agonists in the spinal cord of mu-opioid receptor knockout mice.
Narita M; Mizoguchi H; Narita M; Sora I; Uhl GR; Tseng LF
Br J Pharmacol; 1999 Jan; 126(2):451-6. PubMed ID: 10077238
[TBL] [Abstract][Full Text] [Related]
9. [(35)S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord.
Madia PA; Navani DM; Yoburn BC
Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
[TBL] [Abstract][Full Text] [Related]
10. Activation of G-proteins in the mouse pons/medulla by beta-endorphin is mediated by the stimulation of mu- and putative epsilon-receptors.
Mizoguchi H; Narita M; Nagase H; Tseng LF
Life Sci; 2000 Oct; 67(22):2733-43. PubMed ID: 11105989
[TBL] [Abstract][Full Text] [Related]
11. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
Traynor JR; Nahorski SR
Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
[TBL] [Abstract][Full Text] [Related]
12. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
Emmerson PJ; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
J Pharmacol Exp Ther; 1996 Sep; 278(3):1121-7. PubMed ID: 8819494
[TBL] [Abstract][Full Text] [Related]
13. Involvement of spinal protein kinase Cgamma in the attenuation of opioid mu-receptor-mediated G-protein activation after chronic intrathecal administration of [D-Ala2,N-MePhe4,Gly-Ol(5)]enkephalin.
Narita M; Mizoguchi H; Narita M; Nagase H; Suzuki T; Tseng LF
J Neurosci; 2001 Jun; 21(11):3715-20. PubMed ID: 11356858
[TBL] [Abstract][Full Text] [Related]
14. Relationship of mu opioid receptor binding to activation of G-proteins in specific rat brain regions.
Maher CE; Selley DE; Childers SR
Biochem Pharmacol; 2000 Jun; 59(11):1395-401. PubMed ID: 10751548
[TBL] [Abstract][Full Text] [Related]
15. Effects of sodium on agonist efficacy for G-protein activation in mu-opioid receptor-transfected CHO cells and rat thalamus.
Selley DE; Cao CC; Liu Q; Childers SR
Br J Pharmacol; 2000 Jul; 130(5):987-96. PubMed ID: 10882382
[TBL] [Abstract][Full Text] [Related]
16. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
17. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
Liu JG; Prather PL
Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
[TBL] [Abstract][Full Text] [Related]
18. Autoradiographic distribution of mu-, delta- and kappa 1-opioid stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in human frontal cortex and cerebellum.
Platzer S; Winkler A; Schadrack J; Dworzak D; Tölle TR; Zieglgänsberger W; Spanagel R
Neurosci Lett; 2000 Apr; 283(3):213-6. PubMed ID: 10754225
[TBL] [Abstract][Full Text] [Related]
19. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
Liu JG; Prather PL
J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
[TBL] [Abstract][Full Text] [Related]
20. mu-opioid receptor and alpha2-adrenoceptor agonist stimulation of [35S]GTPgammaS binding to G-proteins in postmortem brains of opioid addicts.
Meana JJ; González-Maeso J; García-Sevilla JA; Guimón J
Mol Psychiatry; 2000 May; 5(3):308-15. PubMed ID: 10889534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
